Malignant Solid Tumors Clinical Trials
2 recruiting trials for Malignant Solid Tumors. Eligibility criteria explained in plain English.
TrialFinderData lists 2 Malignant Solid Tumors clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Research is led by N.N. Petrov National Medical Research Center of Oncology (1), Tianjin Medical University Cancer Institute and Hospital (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is PD-1 and PD-L1 inhibitor (drug, 1 trial), followed by Targeted drugs, chemotherapy drugs.
Track Malignant Solid Tumors trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
Biobank and Register of Patients With Agresive Tumors for Translational and Analytical Research
The investigators will collect biosamples of patient blood and tumour tissue for further immunological analysis of blood cell subpopulations, immunosupressive factors...
The Effect of Serum Ferritin in irAE
This is a prospective clinical study to clarify serum ferritin as a biomarker for the diagnosis, differential diagnosis and prognosis of immune-related adverse event(irAE).
Explore Other Conditions
Frequently Asked Questions
There are currently 2 clinical trials for Malignant Solid Tumors, with 2 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Malignant Solid Tumors, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Malignant Solid Tumors, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.